

REF RX7038, RX7048
100 Specimens
R_X Only

IVD

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit

For Emergency Use Authorization (CUA, 2nly

Instructions for Use

ntended Use · · · · · · · · · · · · · · · · · · ·
Summary and Explanation · · · · · · · · · · · · · · · · · · ·
Principles of the Procedure · · · · · 3
Materials Required (Provided) · · · · · · · · · · · · · · · · · · ·
Materials Required (Not Suppled)
Warnings and Precautions · · · · · · · · 4
Reagent Storage, Harring, and Sability 5
Specimen Collegian, Handling of Storage · · · · · · · · 6
Reagent and ontrols eparation 6
Nucleic Acid Lara Jon 7
Assay Set 1 7
erpretation of Reseats and Reporting · · · · · · · · · · · · · · · · · · ·
Que ity ontrol
Limitatins · · · · · · · · · · · · · · · · · · ·
Conditions of Authorization for the Laboratory · · · · · · · · · · · · · 15
Performance Characteristics · · · · · · · · · · · · · · · · · · ·
Disposal · · · · · · · · · · · · · · · · · · ·
References · · · · · · · · · · · · · · · · · · ·
Revision History······ 19
Contact Information, Ordering, and Product Support · · · · · · · · · · · · 19
Trademarks · · · · · · · · 20
Symbols

Intended Use

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from the SARS-CoV-2 in nasal, nasopharyngeal, oropharyngeal swab specimens, and bronchoalveolar lavage from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in nasal, nasopharyngeal, oropharyngeal swab specimens, and bronchoalveolar lavage during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Laboratories within the United States and its pries are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used by the subasis for patient management decisions. Negative results must be combined with clinical observations, patient history, as Versiemiological information.

The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) etection it is in 2-nded for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and *in vitro* diagnostic procedures. The ScienCell™ SARS-CoV-2 Coronavirus scales are pCR (RT-qPCR) Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization.

<u>Summary and Explanation</u>

The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT CR (RT-qPC) Detection Kit is a molecular *in vitro* diagnostic test that aids in the detection of SARS-CoV-2 RNA and is base on widely used nucleic acid amplification technology and the standard hydrolysis probe system known as TaqMa ® Technology, with primer/probe sets listed below. Each probe contains double quenchers (ZEN and 3/AE S).

RX7038-N1, RX7038-N2, and RY 338-RP primer/probe sets in ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (catala #RX7 38)

in quely beteetion in feature	
	orward: AC CCC AAA ATC AGC GAA AT
RX7038-N1 primer/pr Je se	Terra TCT GGT TAC TGC CAG TTG AAT CTG
	Pros. FAM-ACC CCG CAT-ZEN-TAC GTT TGG TGG ACC-3IABkFQ
	rward: TTA CAA ACA TTG GCC GCA AA
RX7038-N2 primer/pro (set	Reverse: GCG CGA CAT TCC GAA GAA
	<i>Probe</i> : FAM-ACA ATT TGC-ZEN-CCC CAG CGC TTC AG-3IABkFQ
•	Forward: AGA TTT GGA CCT GCG AGC G
RX7038-RP primer/probe set	Reverse: GAG CGG CTG TCT CCA CAA GT
	<i>Probe</i> : FAM-TTC TGA CCT-ZEN-GAA GGC TCT GCG CG-3IABkFQ

Multiplex primer/probe sets in ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7048)

	Forward: GAC CCC AAA ATC AGC GAA AT
N1-FAM primer/probe set	Reverse: TCT GGT TAC TGC CAG TTG AAT CTG
	<i>Probe</i> : FAM-ACC CCG CAT-ZEN-TAC GTT TGG TGG ACC-3IABkFQ
N2-FAM primer/probe set	Forward: TTA CAA ACA TTG GCC GCA AA

	Reverse: GCG CGA CAT TCC GAA GAA
	<i>Probe</i> : FAM-ACA ATT TGC-ZEN-CCC CAG CGC TTC AG-3IABkFQ
	Forward: AGA TTT GGA CCT GCG AGC G
RP-HEX primer/probe set	Reverse: GAG CGG CTG TCT CCA CAA GT
	<i>Probe</i> : HEX-TTC TGA CCT-ZEN-GAA GGC TCT GCG CG-3IABkFQ

Principles of the Procedure

The primer/probe sets (catalog #RX7038-N1 and #RX7038-N2, or N1-FAM and N2-FAM) target coronavirus SARS-CoV-2 nucleocapsid (N) gene, and the other one (catalog #RX7038-RP, or #RP-HEX) targets human RPP30 gene and serves as an internal control to assess specimen quality. In addition, a non-infectious positive control and nuclease-free water are included in the kit. The non-infectious positive control also serves as an RNA extraction precedural control.

RNA isolated from respiratory specimens is purified with Viral RNA Isolation Kit (Scientific Scientific Scient cell, catalo (MB891) or QIAamp® DSP Viral RNA Mini kit (Qiagen, catalog #61904) following manufacturer's procedure **Rurified RN** is subsequently reverse transcribed to cDNA and amplified in Roche LightCycler® 96 Real-Time with L htCycler® Software 1.01.01.0050 using One-Step TagProbe RT-gPCR Master Mix (catalog #MB2 cess, the primers and the probe anneal to target cDNA sequences with the probe located between the rward and reverse primers. During the extension step of each PCR cycle, while elongating the primers, the 5' no se activ of Taq polymerase degrades the probe, causing the FAM or HEX reporter dye to separate from the quenche nd 3IABkFQ), generating a ed at measurable fluorescent signal. Fluorescence intensity is quantil ach PCR cyc by Roche LightCycler® 96 Real-Time PCR System with LightCycler® Software 1.01.01.0050.

Materials Required (Provided)

ScienCell™ SARS-CoV-2 Coronavirus Real-time R PCR X-qPCP Detection Kit (catalog #RX7038) - Singleplex kit

Catalog #	Component	Quantity
MB802a	One-Step TaqProbe A. RCR Mater Mix, 4x	1.5 mL
RX7038-N1	N gene prince/probe set 1, lyophilized	1 nmole of each primer, 0.25 nmoles of probe per vial (100 reactions). Dissolving in 200 μL of H_2O yields 5μM of each primer and 1.25 μM of probe. Final concentration in each RT-qPCR reaction is 500 nM of each primer and 125 nM of probe.
RX7038-N2	lyoper zed	1 nmole of each primer, 0.25 nmoles of probe per vial (100 reactions). Dissolving in 200 μ L of H ₂ O yields 5 μ M of each primer and 1.25 μ M of probe. Final concentration in each RT-qPCR reaction is 500 nM of each primer and 125 nM of probe.
RX7038-RP	Human RPP30 gene primer/probe set, lyophilized	1 nmole of each primer, 0.25 nmoles of probe per vial (100 reactions). Dissolving in 200 μ L of H ₂ O yields 5 μ M of each primer and 1.25 μ M of probe. Final concentration in each RT-qPCR reaction is 500 nM of each primer and 125 nM of probe.
RX7038-H2O	Nuclease-free H₂O	8 mL
RX7038-Pos	Positive control (non-infectious RNA spiked into human small airway epithelial cells)	200 μL, RNA: 500 – 1,000 copies/μL Cells: 200-300 counts /μL

Catalog #	Component	Quantity
MB802a	One-Step TaqProbe RT-qPCR Mater Mix, 4x	1.5 mL
RX7048-MPP	Multiplex primer/probe sets consisting of N gene primer/probe set 1, N gene primer/probe set 2, Human RPP30 gene primer/probe set, Lyophilized	1 nmole of each primer, 0.25 nmoles of probe per vial (100 reactions). Dissolving in 600 μ L of H ₂ O yields 5 μ M of each primer and 1.25 μ M of probe. Final concentration in each RT-qPCR reaction is 500 nM of each primer and 125 nM of probe.
RX7048-H2O	Nuclease-free H ₂ O	4 mL
RX7048-Pos	Positive control (non-infectious RNA spiked into human small airway epithelial cells)	200 μl RNA: 500 – 1,000 copies, Cells: 200-3 1 counts /μL

Materials Required (Not Supplied)

RNA Extraction Options

Manufacturer	Extraction Kit	Catalog
ScienCell	Viral RNA Isolation Kit	14D891
Qiagen	QIAamp® DSP Viral RNA Mini kit	61904

Equipment and Consumables

- LightCycler® 96 Real-Time PCR System with LahtCycler® S tware 1.01.01.0050 (Roche, catalog #05815916001)
- Vortex mixer
- Microcentrifuge
- Micropipettes (2 or 10 μL, 200 μL a. 1000 L)
- Multichannel micropipet s (5-50 μl)
- Racks for 1.5 mL microentrifus tubes
- 2 x 96-well -20°C cold bit
- 96-well PCR rg 2000 lates ach catalog #04729692001)
- LightCycle 8-Tube <u>trips</u> (white) (Roche, catalog #06612601001)
- Aerosol bark pri ette tips
- 1.5 mL microcel ifuge tubes (DNase/RNase free)
- Disposable powder ee gloves and surgical gowns
- 10% bleach (1:10 dilution of commercial 5.25-6.0% hypochlorite bleach)
- DNAZap™ (Ambion, catalog #AM9890) or equivalent
- RNAse Away™ (Fisher Scientific, catalog #21-236-21) or equivalent

Warnings and Precautions

- For use under an Emergency Use Authorization (EUA) only.
- For in vitro diagnostic use (IVD).
- For prescription use only.

- The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit has not been FDA cleared or approved; the test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, and meet the requirements to perform high complexity tests.
- The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- Handle all specimens as if infectious using safe laboratory procedures. Refer to CDC Interim Laboratory Biosafety
 Guidelines for Handling and Processing Specimens Associated with SARS-CoV-2
 https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.htm
- Proper personal protective equipment including lab coats, gowns, gloves, exprotection, and a biological safety cabinet are recommended for manipulation of clinical specimens. Ref. to CDC psafety Microbiological and Biomedical Laboratories (BMBL) 5th Edition https://www.cdc.gov/b.ds/BMPL.htm
- Perform all manipulations of live virus samples within a Class IJ (igher siological safety cabinet (BSC).
- Laboratories within the United States and its territories are required report results to the appropriate public health authorities.
- PCR-based detection technologies are sensitive to acclain that anti-mination of previous PCR products. False positive results could occur if either the clinical speciments are real-time reagents become contaminated.
 - Perform for assay setup and handling nucle acids a separate areas. Workflow in the laboratory should proceed in a unidirectional number. Use a parate and dedicated equipment and supplies in each area.
 - Do not substitute or mix reagen from different le lots or from other manufacturers.
 - Only use aerosol barrier pipette tos and change tips between liquid transfers.
 - Good laboratory techniques should be followed to minimize the risk of cross-contamination between samples, and the incovertence trock ction of nucleases into samples. Proper aseptic technique should always be used then working with nucleic acids.
 - Wear a clean to coat and powder-free disposable gloves when setting up assays, and change gloves between <u>sample</u> and whenever contamination is suspected.
 - o Keep ager and hartio tubes capped or covered as much as possible.
 - Was surfaces, pipettes and centrifuges should be cleaned and decontaminated with cleaning products such as 1% a bies. "DNAZap™" or "RNase AWAY®" to minimize risk of nucleic acid contamination.

 Residble pleach should be removed using 70% ethanol.
- Dispose of unused treagents and human specimens according to local, state, and federal regulations.

Reagent Storage, Handling, and Stability

- Handle all specimens as if infectious using safe laboratory procedures. Refer to CDC Interim Laboratory Biosafety
 Guidelines for Handling and Processing Specimens Associated with SARS-CoV-2
 https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html.
- Upon receipt, store the one-step TaqProbe RT-qPCR master mix (catalog #MB802a) and primer/probe sets (catalog #RX7038-N1, RX7038-N2, and RX7038-RP, or catalog #RX7048-MPP) at -20°C in a manual defrost freezer, the positive control (catalog #RX7038-Pos or catalog #RX7048-Pos) at -80°C, and nuclease-free H₂O (catalog #RX7038-H2O or catalog #RX7048-H2O) at 4°C until ready to use.
- Do not use the kit after the indicated expiry date.

- Aliquot primer/probe sets as needed once rehydrated. Do not freeze-and-thaw primer/probe set for more than once.
- Protect primer/probe sets, lyophilized or rehydrated, from light.
- Keep Primers, probes (including aliquots), control samples, RNA, and enzyme master mix cold at all times during preparation and use.

Specimen Collection, Handling, and Storage

- Human nasal, nasopharyngeal, oropharyngeal swab specimens, and bronchoalveolar lavage may be used with the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit.
- Inadequate or inappropriate specimen collection, storage, and transport are likely to yield false test results.
 Training in specimen collection is highly recommended due to the importance of the importa
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinial Specime from Patients Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV) https://www.co.gov/co/navirus/2019-nCoV/guidelines-clinical-specimens.html
- Specimens must be packaged, shipped, and transported according to the current edition of the International Air Transport Association (IATA) Dangerous Goods Regulation. Follow should regulations for UN 3373 Biological Substance, Category B when sending potential SARS-CoV-2 specimens.
- Specimens can be stored at 2-8 °C for up to 72 hours a price section. If a delay in extraction is expected, store specimens at -80 °C.
- Extracted nucleic acid should be stored at -80.

Reagent and Controls Preparation

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7038) No Template Control (NTC) Preparation:

- 1. NTC is nuclease-free H (catalog #n. 101 -H2O).
- 2. Aliquot in small volves (approximately 900 μl each).

Primer/probe Set Prepair on:

- 1. Upon receit, sto lyoph receiprimer/probe sets at -20 °C.
- 2. Prior to se, allow the prime / probe sets (catalog #RX7038-N1, RX7038-N2, and RX7038-RP) to warm to room temperature in the base.
- 3. Centrifuge to vials at 1,500x g for 1 minute.
- 4. Add 200 μl no pase-free H₂O (catalog #RX7038-H2O) to N gene primer/probe set 1 (lyophilized, catalog #RX7038-N1) and allow to rehydrate for 15 min at room temperature to make N1 primer/probe stock solution. Aliquot as needed. Store at -20°C in a manual defrost freezer. Avoid repeated freeze-and-thaw cycles. Maintain cold and in the dark when thawed.
- 5. Add 200 μl nuclease-free H₂O (catalog #RX7038-H2O) to N gene primer/probe set 2 (lyophilized, catalog #RX7038-N2) and allow to rehydrate for 15 min at room temperature to make N2 primer/probe stock solution. Aliquot as needed. Store at -20°C in a manual defrost freezer. Avoid repeated freeze-and-thaw cycles. Maintain cold and in the dark when thawed.
- 6. Add 200 μ l nuclease-free H₂O (catalog #RX7038-H2O) to Human RPP30 gene primer/probe set (lyophilized, catalog #RX7038-RP) and allow to rehydrate for 15 min at room temperature to make RP primer/probe stock solution. Aliquot as needed. Store at -20°C in a manual defrost freezer. Avoid repeated freeze-and-thaw cycles. Maintain cold and in the dark when thawed.

Positive Control Preparation:

- 1. Positive control (catalog #RX7038-POS) is non-infectious RNA spiked into human small airway epithelial cells.
- 2. Aliquot in small volumes (approximately 18 μ L each), and store at -80°C. Do not freeze-and-thaw for more than once.

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7048) No Template Control (NTC) Preparation:

- 1. NTC is nuclease-free H₂O (catalog #RX7048-H2O).
- 2. Aliquot in small volumes (approximately 600 μl each).

Primer/probe Set Preparation:

- 1. Upon receipt, store lyophilized primer/probe sets at -20 °C.
- 2. Prior to use, allow the multiplex primer/probe sets (catalog #RX7048-10 °C) to warm room temperature in the dark.
- 3. Centrifuge the vials at 1,500x g for 1 minute.
- 4. Add 600 μl nuclease-free H₂O (catalog #RX7048-H2O) to the dultiple primer/pobe sets (catalog #RX7048-MPP) and allow to rehydrate for 15 min at room temperature to page multiplex primer/probe stock solution. Aliquot as needed. Store at -20°C in a manual defrost free: ar. Avoids peated freeze-and-thaw cycles. Maintain cold and in the dark when thawed.

Positive Control Preparation:

- 1. Positive control (catalog #RX7048-POS) is in-infectives had spiked into human small airway epithelial cells.
- 2. Aliquot in small volumes (approximately 10 μL each) and store at -80°C. Do not freeze-and-thaw for more than once.

Nucleic Acid Extraction

For RNA extraction from human specimens, a recommend using Viral RNA Isolation Kit (ScienCell, catalog #MB891) or QIAamp® DSP Viral RNA Mini kit (O'r gen, catalog \$1,04) and following manufacturer's protocol.

Assay Set Up

ScienCell™ SARS-C 7-2 Commavirus real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7038)

- 1. Clean at decontract all work surfaces, pipettes, centrifuges, and other equipment prior to use to minimize the ask of nucleic acid cross-contamination.
- 2. In the reagent at-up clean area, thaw primer/probe sets, one-step RT-qPCR master mix and place them on ice or cold-block. Mix well by inversion 5 times. *Do not vortex*.
- 3. Briefly spin them for 5 seconds, followed by placing them and H_2O on ice or cold-block. Keep cold during preparation and use.
- 4. Label one 1.5 mL microcentrifuge tube for each primer/probe set.
- 5. Determine the number of reactions (N) to set up per test run. It is necessary to make excess reaction mix for the two control samples, the non-infectious positive control (catalog #RX7038-Pos) and H₂O (catalog #RX7038-H2O) as the No Template Control (NTC). Use the following guide to determine N:
 - a. If number of samples (n) including controls equals 3 through 12, then N = n + 1
 - b. If number of samples (n) including controls equals 13 through 24, then N = n + 2
 - c. If number of samples (n) including controls is 25 through 32, then N = n + 3. One 96-well plate can hold up to 32 samples.

6. For each primer/probe set, calculate the amount of each reagent to be added for each reaction mixture (N = # of reactions) as shown in the table below. Add reagents into each respectively labeled 1.5 mL microcentrifuge tube. Mix reaction mixtures by pipetting up and down. *Do not vortex*. Centrifuge for 5 seconds to collect contents at the bottom of the tube, and then place the tubes in a cold rack.

Reagent	Volume of Reagent Added
Primer/probe stock solution (N1, N2, or RP)	Ν x 2 μl
One-step RT-qPCR Master mix, 4x (catalog #MB802a)	Ν x 5 μl
Nuclease-free H ₂ O (catalog #RX7038-H2O)	Ν x 8 μl
Total volume	Ν x 15 μl

7. For each control sample and test specimen, three RT-qPCR reactions need to be repared, one with N1 primer/probe stock solution, one with N2 primer/probe stock solution, an one with NP primer/probe stock solution. Dispense 15 μ L of each reaction mixture into the appropriate wells using cross the column as the example shown below.

Example of Reaction Mixture Plate Set-Up for 28 samples

	1	2	3	4	5	6	7	8		10	11	12
Α	N1	N2	RP	N1	N2	RP		N2	RP	N1	N2	RP
В	N1	N2	RP	N1	N2	RP	11	N2	RP	N1	N2	RP
С	N1	N2	RP	N1	N2	RP	r.	N2	RP	N1	N2	RP
D	N1	N2	RP	N1	12	ВÞ	N1	N2	RP	N1	N2	RP
E	N1	N2	RP	N1	Λ	RP	N1	N2	RP			
F	N1	N2	P	N1	10	RP	N1	N2	RP			
G	N1	N2	RP	N1	N2	RP	N1	N2	RP			
Н	N1	N2	Y	N1	N2	RP	N1	N2	RP			

8. Prior to having to the cheic acid handling area, prepare the No Template Control (NTC) reactions for row #A in the reage set-up clean area by pipetting 5 μL of nuclease-free water into the NTC sample wells as the example show, below. Securely cap NTC wells before proceeding.

	1	2	3	4	5	6	7	8	9	10	11	12
Α	NTC	NTC	NTC									
В												
С												
D												
E												
F												

G						
Н						

- 9. Cover the entire reaction plate and move the reaction plate to the specimen nucleic acid handling area.
- 10. Gently vortex nucleic acid sample tubes for approximately 5 seconds.
- 11. Centrifuge for 5 seconds to collect contents at the bottom of the tube.
- 12. After centrifugation, place extracted nucleic acid sample tubes in the cold rack.
- 13. Samples should be added to wells to the specific assay that is being tested as illustrated in the table below. Carefully pipette 5 μ L of the first sample into all the wells labeled for that sample (i.e. Sample "S1" down row #B). Keep other sample wells covered during addition. Change tips after each addition.

	1	2	3	4	5	6	7	8	9		11	12
Α	NTC	NTC	NTC	S8	S8	S8	S16	S16	S1	S24	24	S24
В	S1	S1	S1	S9	S9	S9	S17	S17	\$17	S25	5 5	S25
С	S2	S2	S2	S10	S10	S10	S18	Ş	S1	52	S26	S26
D	S3	S3	S3	S11	S11	S11	S19	51	<i>s</i> 19			
E	S4	S4	S4	S12	S12	S12	S20	S20	250			
F	S5	S5	S5	S13	S13	S13	V21		S21			
G	S6	S6	S6	S14	S14		S2.	S22	S22			
Н	S7	S7	S7	S15	S15	S15	3	523	S23			

- 14. Securely cap the wells to which the amp has been a ded to prevent cross contamination and to ensure sample tracking.
- 15. Change gloves often and when necess by to avoid contamination.
- 16. Repeat steps #13 and #14 for the remaining samples.
- 17. Cover the entire reaction plate and sixe the reaction plate to the positive template control handling area.
- 18. Pipette 5 μL of the pre-infectious positive control (catalog #RX7038-Pos) to the sample wells of shown in the table below. Secure y cap years after addition of the positive control.

NOTE: If using 8-tube trues, label the TAB of each strip to indicate sample position. **DO NOT LABEL THE TOPS**OF THE REAL TO TUBE

	1	2	3	4	5	6	7	8	9	10	11	12
Α	NTC	\rac{1C}{}	NTC	S8	S8	S8	S16	S16	S16	S24	S24	S24
В	S1	1	S1	S9	S9	S9	S17	S17	S17	S25	S25	S25
С	S2	S2	S2	S10	S10	S10	S18	S18	S18	S26	S26	S26
D	S3	S3	S3	S11	S11	S11	S19	S19	S19	Pos	Pos	Pos
E	S4	S4	S4	S12	S12	S12	S20	S20	S20			
F	S5	S5	S5	S13	S13	S13	S21	S21	S21			
G	S6	S6	S6	S14	S14	S14	S22	S22	S22			
Н	S7	S7	S7	S15	S15	S15	S23	S23	S23			

19. Briefly centrifuge reaction plate or strips for 30 seconds at 500 x g, 4°C. After centrifugation return to cold

rack.

20. Setup RT-qPCR reactions as shown in the table below.

Instrument settings for RT-qPCR reactions. Fluorescence data (FAM) should be collected during the data acquisition step.

Step	Temperature	Time	Number of cycles
UNG incubation	25°C	2 min	1
Reverse transcription	50°C	15 min	1
Enzyme activation	95°C	2 min	1
Denaturation	95°C	3 sec	
Annealing and extension	55°C	30 sec	45
Data acquisition	Plate read,	detector (FAM)	

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection it (cathog #RX7048)

- 1. Clean and decontaminate all work surfaces, pipettes, centrifug ar other equipment prior to use to minimize the risk of nucleic acid cross-contamination.
- 2. In the reagent set-up clean area, thaw primer/probe sets one-step N of R master mix and place them on ice or cold-block. Mix well by inversion 5 times. **Do not vertice**
- 3. Briefly spin them for 5 seconds, followed by placing the or nd H₂O or ice or cold-block. Keep cold during preparation and use.
- 4. Label one 1.5 mL microcentrifuge tube for eaction makers (M)
- 5. Determine the number of reactions (N) to set up per tearrun. It is necessary to make excess reaction mix for the two control samples, the non-infection positive control (catalog #RX7048-Pos) and H₂O (catalog #RX7048-H2O) as the No Template Control (1995). We the following guide to determine N:
 - a. If number of samples (n) including controls equals 3 through 12, then N = n + 1
 - b. If number of samples (n) increases collapse equals 13 through 24, then N = n + 2
 - c. If number of sample (n) including α ols equals 25 through 36, then N = n + 3
 - d. If number of samples (n) $\frac{1}{2}$ luding controls equals 37 through 48, then N = n + 4
 - e. If number of same s = 1 (including controls equals 49 through 60, then N = n + 5)
 - f. If number mple n including controls equals 61 through 72, then N = n + 6
 - g. If number of samples (h) and uding controls equals 73 through 84, then N = n + 7
 - h. If not ber of a = bs (n) including controls equals 85 through 96, then N = n + 8. One 96-well plate can hold up to 6 samples.
- 6. Calculate the arount of each reagent to be added for each reaction mixture (N = # of reactions) as shown in the table below. Add reagents into the labeled 1.5 mL microcentrifuge tube. Mix reaction mixtures by pipetting up and down. *Do not vortex*. Centrifuge for 5 seconds to collect contents at the bottom of the tube, and then place the tube in a cold rack.

Reagent	Volume of Reagent Added
Multiplex primer/probe stock solution (MPP)	Ν x 6 μl
One-step RT-qPCR Master mix, 4x (catalog #MB802a)	Ν x 5 μl
Nuclease-free H ₂ O (catalog #RX7048-H2O)	Ν x 4 μl
Total volume	N x 15 μl

7. For each control sample and test specimen, one RT-qPCR reaction needs to be prepared. Dispense 15 μ L of the reaction mixture (RM) into the appropriate wells going across the column as the example shown below.

Example of Reaction Mixture (RM) Plate Set-Up for 26 samples

	1				,ac							
	1	2	3	4	5	6	7	8	9	10	11	12
Α	RM	RM	RM	RM								
В	RM	RM	RM	RM								
С	RM	RM	RM	RM								
D	RM	RM	RM	RM								
E	RM	RM	RM									
F	RM	RM	RM									
G	RM	RM	RM									
Н	RM	RM	RM									

8. Prior to moving to the nucleic acid handling area, prepare new plate Control (NTC) reaction for well #A1 in the reagent set-up clean area by pipetting 5 uL on sclease-free water into the NTC sample well as the example shown below. Securely cap NTC well before rock king.

	1	2	3	4	5	6	8	9	10	11	12
Α	NTC										
В											
С											
D											
E											
F											
G											
Н											

- 9. Cover the entire reaction plate and move the reaction plate to the specimen nucleic acid handling area.
- 10. Gently vortex nucleic acid sample tubes for approximately 5 seconds.
- 11. Centrifuge for 5 seconds to collect contents at the bottom of the tube.
- 12. After centrifugation, place extracted nucleic acid sample tubes in the cold rack.
- 13. Samples should be added to wells to the specific assay that is being tested as illustrated in the table below. Carefully pipette 5 μ L of the sample into the well labeled for that sample (i.e. Sample "S1" down row #B). Keep other sample wells covered during addition. Change tips after each addition.

	1	2	3	4	5	6	7	8	9	10	11	12
Α	NTC	S8	S16	S24								

В	S1	S9	S17	S25				
С	S2	S10	S18	S26				
D	S3	S11	S19					
E	S4	S12	S20					
F	S5	S13	S21					
G	S6	S14	S22					
Н	S7	S15	S23					

- 14. Securely cap the wells to which the sample has been added to prevent cross contamination and to ensure sample tracking.
- 15. Change gloves often and when necessary to avoid contamination.
- 16. Repeat steps #13 and #14 for the remaining samples.
- 17. Cover the entire reaction plate and move the reaction plate to the ositive implate introl handling area.
- 18. Pipette 5 μL of the non-infectious positive control (catalog #RXZ 48-Post to the autole well of shown in the table below. Securely cap wells after addition of the positive aptrol.

NOTE: If using 8-tube strips, label the TAB of each strip to indicate ample position. **DO NOT LABEL THE TOPS OF THE REACTION TUBES!**

	1	2	3	4	5	6	7	8	Y	10	11	12
Α	NTC	S8	S16	S24								
В	S1	S9	S17	S25			1.					
С	S2	S10	S18	S26								
D	S3	S11	S19	Pos								
E	S4	S12	S20 .									
F	S5	S13	ST		V							
G	S6	S14 (S22									
Н	S7	CIF	X									

- 19. Briefly htrifuge eaction plate or strips for 30 seconds at 500 x g, 4°C. After centrifugation return to cold rack.
- 20. Setup RT-qPt reactions as shown in the table below.

Instrument set gs for RT-qPCR reactions. Fluorescence data (both FAM and HEX) should be collected during the data acquisition step.

Step	Temperature	Time	Number of cycles
UNG incubation	25°C	2 min	1
Reverse transcription	50°C	15 min	1
Enzyme activation	95°C	2 min	1
Denaturation	95°C	3 sec	
Annealing and extension	55°C	30 sec	45
Data acquisition	Plate read, de	tector (FAM and HEX)	

Interpretation of Results and Reporting

ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7038)

 Results interpretation of the two controls (catalog #RX7038-Pos and #RX7038-H2O) included in the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit

Sample	RX7038-N1	RX7038-N2	RX7038-RP	Results Interpretation
DV7020 D	+	+	+	Expected
RX7038-Pos	-	-	-	Reverse transcription and/or PCR failed
DV7020 II O	-	-	-	pected
RX7038-H₂O	If anyone	of three targets	is positive	P agenty tontaminate

Note: a Ct value < 40.00 is considered positive

Note: Any controls not showing the expected results is an indicate of that pagent(s) and/or equipment(s) are not functioning properly. The run is invalid and should be repeated.

Results interpretation for patient specimens

				•
RX7038- N1	RX7038- N2	RX7038- RP	Results Interpretation	Action
+	+	±	SARS-Co 2 detected	Report results.
	ne of two s positive	±	SARS-C V-2 detected	Report results.
-	-	+	SARL ToV-2), Note a	Report results.
-	-	J	In alid result	Repeat extraction and RT-qPCR. If the repeated result remains invalid, consider collecting a new specimen from the patient.

Note: a Ct value < 40.00 considered positive

ScienCell™ SARS-CoV-2 Caravirus Real-time RT-PCR (RT-qPCR) Detection Kit (catalog #RX7048)

 Results interpretation of the controls (catalog #RX7048-Pos and #RX7048-H2O) included in the ScienCell SARS-110 Soronavirus Real-time RT-PCR (RT-qPCR) Detection Kit

Chann	FAM (N1, N2)	Hex (RP)	Results Interpretation		
RX7048-Pos	+	+	Expected		
RA7048-P05	-	-	Reverse transcription and/or PCR failed		
DV7049 II O	-	-	Expected		
RX7048-H₂O	If anyone of two	targets is positive	Reagent(s) contaminated		

Note: a Ct value < 40.00 is considered positive

Note: Any controls not showing the expected results is an indication that reagent(s) and/or equipment(s) are not functioning properly. The run is invalid and should be repeated.

Results interpretation for patient specimens

FAM (N1, N2)	HEX (RP)	Results Interpretation	Action
+	±	SARS-CoV-2 detected	Report results.
-	+	SARS-CoV-2 not detected	Report results.
-	-	Invalid result	Repeat extraction and RT-qPCR. If the repeated result remains invalid, consider collecting a new specimen from the patient.

Note: a Ct value < 40.00 is considered positive

Quality Control

- Quality control requirements must be performed in conformance with local, statuted federal regulations or accreditation requirements and the user's laboratory's standard quality control procedures (please refer to 42 CFR 493.1256).
- One positive control and one negative control (provided) must be processed with each rule Quality control procedures are intended to monitor reagent and assay performances for control sult interpretation, refer to section "Interpretation of Results and Reporting".
- Test positive control prior to running diagnostic samples with each to kit lot to insure all reagents and kit components are working properly.
- Good laboratory practice (cGLP) recommends including a positive extraction control in each nucleic acid isolation batch; RX7038-Pos or RX7048-Pos, a positive control (not in reaction) spiked into human small airway epithelial cells) included in the assay kit acts as a serific extraction control.

Limitations

- The use of ScienCell™ SARS-CoV-2 Corc avir. Real-time (T-PCR (RT-qPCR)) Detection Kit as an *in vitro* diagnostic under the FDA Emergency Use Authors Corr (EUA) is limited to laboratories that are certified under the Clinical Laboratory Improvement Americanets of 1988 (CLIA), 42 U.S.C. § 263a, and meet the requirements to perform high complexity tests.
- The ScienCell™ SARS-Cov-2 Corporations Real-time RT-PCR (RT-qPCR) Detection Kit can be used only with the specimens listed in the aten ad Use statement. Other specimen types have not been evaluated and should not be tested with the ssay.
- Samples my a be collected, the ported, and stored using appropriate procedures and conditions. Improper collection, anspect, and ge of specimens may hinder the ability of the assay to detect the target sequences.
- Extraction and amplication of nucleic acid from clinical samples must be performed according the specified methods listed in this procedure. Other extraction approaches and processing systems have not been evaluated.
- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative
 results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of
 organisms are present in the specimen.
- A false positive result may arise from cross contamination during specimen handling or preparation, or between patient samples.

- The impacts of vaccines, antiviral therapeutics, antibiotics, chemotherapeutic or immunosuppressant drugs have not been evaluated. The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit cannot rule out diseases caused by other bacterial or viral pathogens.
- Negative results do not preclude infection with SARS-CoV-2 virus, and should not be the sole basis of a patient management decision.
- Results from the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit should be used as an adjunct to clinical observations and other information available to the physician.

Conditions of Authorization for the Laboratory

The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit Letter of the Shorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website: https://www.fda.gov/medical-devices/coronavirus-dk.gse-2019-cold-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas

To assist clinical laboratories using the ScienCell™ SARS-CoV-2 Coronavirus real-time RT-PCR (7-qPCR) Detection Kit, the relevant Conditions of Authorization are listed below.

- Authorized laboratories¹ using the ScienCell™ SARS-CoV-2 Coronavirus Real-th le RT-PCR (RT-qPCR) Detection Kit will include with result reports of the ScienCell™ SARS-Co (-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit all authorized Fact Sheets. Under exigent to use ther appropriate methods for disseminating these Fact Sheets may be used, with a pay in sude mass media.
- Authorized laboratories will perform the ScienCell™ SAR CoV- Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit as outlined in the ScienCell™ S RS-CoV-2 Co pnavirus Real-time RT-PCR (RT-qPCR) Detection Kit Instructions for Use. Deviations from the authorized procedures, including the authorized RT-PCR instruments, authorized extraction methods, authorized clinical-specimen types, authorized control materials, authorized other ancillary reagents and authorized miterials required to perform the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCr) Detection That not permitted.
- Authorized laboratories that receive the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR)

 Detection Kit must note the elevant public health authorities of their intent to run the test prior to initiating testing.
- Authorized boratores using the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit
 will have a processor pressor reporting test results to healthcare providers and relevant public health
 authorities, as a propriate.
- Authorized laborate es using the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit will collect information on the performance of the test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and ScienCell™ (techsupport@ScienCellonline.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test of which they become aware.
- All laboratory personnel using the test must be appropriately trained in RT-PCR techniques and use appropriate
 laboratory and personal protective equipment when handling this kit and use the test in accordance with the
 authorized labeling.

• ScienCell™ Research Laboratories and authorized laboratories using the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

¹The letter of authorization refers to "United States (U. S.) laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests" as "authorized laboratories."

Performance Characteristics

Limit of Detection (LoD):

LoD studies determine the lowest detectable concentration of SARS-CoV-2 that could be reliably detected at least 95% of the time.

SARS-CoV-2 extracted RNA obtained from University of Texas Medical Branch (€ MB) with known titer was spiked into pooled nasopharyngeal matrix. Samples were extracted using the Viral NA Isolation Kit (ScienCell, catalog #MB891) and the QIAamp DSP Viral RNA Mini Kit (Qiagen, catalog #61904). ResPCF assays were performed using the One-Step TaqProbe RT-qPCR Mater Mix, 4x (catalog #MB1 J2a) on the Roche LightCycler® 96 Real-Time PCR System with LightCycler® Software 1.01.01.0050 accorded to the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit instructions for use

A preliminary LoD was determined testing four replicates 3-for serial dilutions of quantified SARS-CoV-2 extracted RNA. A confirmation of the LoD was determined us x -fold serial dilution RNA samples with 20 extracted replicates. The LoD was determined as the Low scone attration where ≥ 95% (19/20) of the replicates were positive by the ScienCell™ SARS-CoV-2 Core lavirus Real time. S-PCR (RT-qPCR) Detection Kit as per the results interpretation algorithm.

Limit of Detection confirmation of the Sciencell Cell (RS-Co) 2 Coronavirus Real-time RT-PCR (RT-qPCR)

Detection Kit with SCIENCELL Viral RNA Isolation Kit

Targets		J	38-N1		RX7038-N2			
RNA Concertration (copies)	10 ¹	10 ^{0.5}	10 ⁰	10 ^{-0.5}	10 ^{1.5}	10 ¹	10 ^{0.5}	10 ⁰
JSIN Total	20° U	20/20	20/20	3/20	20/20	20/20	20/20	3/20
M	28.36	30.13	31.95	NA	27.90	29.82	31.91	NA
Sta ard Deviation (Ct)	0.10	0.19	0.88	NA	0.10	0.12	0.53	NA

^aMean Ct reported for dilutions that are ≥95% positive NA: not applicable

Limit of Detection confirmation of the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit with QIAGEN QIAamp DSP Viral RNA Mini Kit

Targets		RX70	38-N1			RX70	38-N2	
RNA Concentration (copies/µL)	10 ¹	10 ^{0.5}	10 ⁰	10 ^{-0.5}	10 ^{1.5}	10 ¹	10 ^{0.5}	10º
Positive/Total	20/20	20/20	20/20	4/20	20/20	20/20	20/20	4/20

Mean Ct ^a	27.31	28.98	30.52	NA	28.16	29.05	31.10	NA
Standard Deviation (Ct)	0.05	0.13	0.20	NA	0.12	0.12	0.49	NA

 a Mean Ct reported for dilutions that are ≥95% positive

NA: not applicable

Limit of Detection of the ScienCell^M SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit as per results interpretation algorithm with both extraction kits is 10° copies/ μ L.

A complete LoD study (preliminary and confirmatory) was repeated with the multiplex kit (ScienCell, catalog #RX7048) in parallel with the previously authorized singleplex kit (ScienCell, catalog #RX7038) using the UTMB virus material and the procedure described earlier.

Limit of Detection confirmation of the ScienCell™ SARS-CoV-2 Coronavirus Relatime RT-PC (RT-qPCR)

Detection Kit using the singleplex kit (ScienCell, catalog #RX7038)

Targets	RX7038-N1			R. 37 8-N2				
RNA Concentration (copies/μL)	10¹	100.5	10°	10-0	1.5	3 ¹	100.5	10 ⁰
Positive/Total	20/20	20/20	20/20	2/20	2 120	20/20	20/20	2/20
Mean Ct ^a	28.24	30.02	37 3		28.48	30.18	30.99	NA
Standard Deviation (Ct)	0.07	0.1	2 19	NA	0.08	0.11	0.19	NA

^aMean Ct reported for dilutions that are ≥9 6 positive

NA: not applicable

Limit of Detection confirmation of the Sciel Cell™ RS-Cell 2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit using the multiplex kit (ScienCell, catalog #RX7048)

Channel (Tragets)	FAM (N1, N2)				
AA Concentration (conles/µL)	10¹	10 ^{0.5}	10 ⁰	10 ^{-0.5}	
Jsitive/T cal	20/20	20/20	20/20	2/20	
lo n Cta	27.29	28.07	28.78	NA	
d Deviation (Ct)	0.13	0.15	0.16	NA	
Control Tested	FAM (N	N1, N2)	HEX	(RP)	
Positive control	21	.14	21	.73	
Negative control	NA		NA		

^aMean Ct reported for dilutions that are ≥95% positive

NA: not applicable

Limit of Detection of the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit as per results interpretation algorithm (ScienCell, catalog #RX7048) with both multiplex and singleplex kits is 10° copy/µL.

Cross-reactivity:

The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit utilizes oligos that have identical sequences to those used in the CDC 2019-Novel Coronavirus (2019-CoV) Real-Time RT-PCR Diagnostic Panel the CDC assay. The cross-reactivity of CDC assay under an EUA has been evaluated and therefore, additional evaluation is not required.

Endogenous Interference Substances Studies:

The ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit uses conventional well-established nucleic acid extraction method that is also authorized with the CDC 2019-Novel Coronavirus (2019-CoV) Real-Time RT-PCR Diagnostic Panel the CDC assay. We do not anticipate interference from common endogenous substances using this method.

Clinical Performance:

Clinical evaluation of the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR \(\int \) tection Kit (ScienCell, catalog #RX7038) was conducted using contrived nasopharyngeal s bs (30 posit es and 30 negatives). The 30 positive samples were spiked by SARS-CoV-2 extracted P ned from niversity of Texas Medical Branch. 20 of the contrived positive samples (Samples #1-20) w ig the SARS-CoV-2 e preparec mples RNA at 1-2x LoD and the rest (Samples #21-30) 10 contrived positive testing range of the SARSCOV-2 Coronavirus Realassay (< 5x LoD). The positive and negative agreements between the time RT-PCR (RT-qPCR) Detection Kit and the expected results a show

Results summary:

	ScienCell™ SARS-CoV (ronavirus Real-time RT-PCR (RT-qPCR) Detection (Control Science)				
SARS-CoV-2 concentration	Results (De ected/Teste	Agreements (95% CI)			
1-2x LoD	20/20	100% (83.9%, 100%)			
3-5x LoD	10/10	100% (72.3%, 100%)			
Negative	30/30³	100% (88.7%, 100%)			

^{*}Negative results detected/tested

Clinical evaluation of the Sciencell™ SARS — Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (ScienCell, catalog #RX7048 was conducted in a blinded fashion using 60 clinical nasopharyngeal swab specimens. Testing was pursormer according to the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit Instruction for Use and patient sample was tested by the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit using both the singleplex (ScienCell, catalog #RX7038) and multiplex (Sciencell, catalog #RX7038) formats and the results of the two were compared as shown below.

Results summa

			RS-CoV-2 Coronavirus Real-time Kit (ScienCell, catalog #RX7038)
		Positive	Negative
ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection	Positive	30	0
Kit (ScienCell, catalog #RX7048)	Negative	0	30
Positive percent agreement (95% CIs)	100% (88.7%		
Negative Percent agreement (95% CIs) 100% (88.7%)		, 100%)	

FDA SARS-CoV-2 Reference Panel Testing

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1),

blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. Samples were extracted using the Viral RNA Isolation Kit (ScienCell, catalog #MB891). RT-qPCR assays were performed in singleplex format (Sciencell, catalog #RX7038) using the One-Step TaqProbe RT-qPCR Mater Mix, 4x (catalog #MB802a) on the Roche LightCycler® 96 Real-Time PCR System with LightCycler® Software 1.01.01.0050 according to the ScienCell™ SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit instructions for use. The results are summarized in the Table below.

Summary of LoD Confirmation Result using the FDA SARS-CoV-2 Reference Panel

Reference Materials Provided by FDA	Specimen Type	Product LoD	Cross-Reactivity
SARS-CoV-2	Spiked pasephanyageal clinical matrix	5.4x10 ² NDV /IIL	Á
MERS-CoV	Spiked nasopharyngeal clinical matrix	N/A	NL

NDU/mL = RNA NAAT detectable units/mL

N/A: Not applicable ND: Not detected

Disposal

Dispose of hazardous or biologically contaminated materials according to the practice of your institution.

References

- 1. Ballew, H. C., et al. "Basic Laboratory Methods in Zirology," D. HS, Public Health Service 1975 (Revised 1981), Centers for Disease Control and Prevention, Atla ta, Georgia 3 333.
- 2. Clinical Laboratory Standards Institute (CLS) "Concction, Transport, Preparation and Storage of Specimens for Molecular Methods: Proposed Guiden "113-A.
- 3. CDC 2019-Novel Coronavirus (2019 nCoV) Rea Time RT-PCR Diagnostic Panel. 2020, US Centers for Disease Control and Prevention (https://www.na.gov/media/134922/download)
- 4. Research Use Only 2019-Nov Coronavirus (2. nCoV) Real-time RT-PCR Primer and Probe Information. 2020, US Centers for Probease Control and Prevention. https://www.cdc.gov/coro.xir//2019-pov/downloads/rt-pcr-panel-primer-probes.pdf

Revision Histor

Revision #	Effect ve Date	Summary of Revisions
1	April 3, 120	Original Instructions for Use
2	May 26, 2020	Addition of an alternative nucleic acid extraction platform
3	August 25, 2020	Addition of a multiplex-format detection kit (catalog #RX7048)

Contact Information, Ordering, and Product Support

For technical and product support, contact

ScienCell Research Laboratories

1610 Faraday Ave

Carlsbad, CA 92008 USA

www.sciencellonline.com

Email: techsupport@sciencellonline.com

Tel: 1-760-602-8549 Fax: 1-760-602-8575

 $\hbox{@2020 ScienCell. All Rights Reserved.}\\$

April 2020 PSRX7038-R3

Trademarks

Trademarks: ScienCell™

All other trademarks that appear in this IFU are the property of their respective owners.

Symbols The following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in this in the following table describes the symbols that may appear on the labeling or in the following table describes the symbols that may appear on the labeling or in the following table describes the symbols that may appear on the following table describes the symbols that may appear on the following table describes the symbols that may appear on the following table des

